Patents Assigned to CVERGENX, INC.
  • Patent number: 11865365
    Abstract: Disclosed herein are methods for personalized treatment of individual patient tumors. A computer software configured to integrate with a radiation therapy treatment planning system is presented. The computer software is configured to: assign a radiation sensitivity index (RSI) of a subject's tumor based at least in part on expression levels of one or more signature genes in the tumor; calculate a recommended personalized radiation dosage (RxRSI) for the subject based at least in part on a pre-determined genomic adjusted radiation dose (GARD) value and the RSI; and provide, to the radiation therapy treatment planning system, the recommended RxRSI as a radiation therapy dose for a radiation plan.
    Type: Grant
    Filed: December 30, 2022
    Date of Patent: January 9, 2024
    Assignee: CVERGENX, INC.
    Inventors: Jacob G. Scott, Javier Torres-Roca
  • Patent number: 11547871
    Abstract: Disclosed herein are methods for personalized treatment of individual patient tumors. In one embodiment, a method of calculating a personalized radiation therapy dosage for a subject comprises determining expression levels of one or more signature genes from a subject's tumor sample, applying a linear regression model to the gene expression levels and assigning a radiation sensitivity index (RSI) to the subject's tumor sample, calculating a genomic adjusted radiation dose (GARD) value based on RSI, radiation dose and fractionation schedule of the subject, and calculating a personalized radiation dosage (RxRSI) for the subject based on a pre-determined GARD value.
    Type: Grant
    Filed: October 21, 2019
    Date of Patent: January 10, 2023
    Assignee: CVERGENX, INC.
    Inventors: Jacob G. Scott, Javier Torres-Roca
  • Publication number: 20200121948
    Abstract: Disclosed herein are methods for personalized treatment of individual patient tumors. In one embodiment, a method of calculating a personalized radiation therapy dosage for a subject comprises determining expression levels of one or more signature genes from a subject's tumor sample, applying a linear regression model to the gene expression levels and assigning a radiation sensitivity index (RSI) to the subject's tumor sample, calculating a genomic adjusted radiation dose (GARD) value based on RSI, radiation dose and fractionation schedule of the subject, and calculating a personalized radiation dosage (RxRSI) for the subject based on a pre-determined GARD value.
    Type: Application
    Filed: October 21, 2019
    Publication date: April 23, 2020
    Applicant: CVERGENX, INC.
    Inventors: Jacob G. Scott, Javier Torres-Roca